再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REGN 再生元制药公司

休市中 12-20 15:59:59 EST

701.85

-6.40

-0.90%

盘后706.33

+4.48+0.64%

19:49 EST

最高717.61	最低700.83	成交量189.00万
今开710.20	昨收708.25	日振幅2.37%
总市值771.26亿	流通市值743.96亿	总股本1.10亿
成交额13.32亿	换手率1.78%	流通股本1.06亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":701.85,"timestamp":1734728399999,"preClose":708.25,"halted":0,"volume":1889990,"hourTrading":{"tag":"盘后","latestPrice":706.33,"preClose":701.85,"latestTime":"19:49 EST","volume":335400,"amount":235410899.51345,"timestamp":1734742188381},"delay":0,"floatShares":106000000,"shares":109889531,"eps":40.428474,"marketStatus":"休市中","marketStatusCode":7,"change":-6.4,"latestTime":"12-20 15:59:59 EST","open":710.2,"high":717.6099,"low":700.83,"amount":1331951080.1025,"amplitude":0.023692,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":40.428474,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":0,"adjPreClose":708.25,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":710.76,"preClose":708.25,"latestTime":"09:29 EST","volume":1526,"amount":1074951.024,"timestamp":1734704999986},"postHourTrading":{"tag":"盘后","latestPrice":706.33,"preClose":701.85,"latestTime":"19:49 EST","volume":335400,"amount":235410899.51345,"timestamp":1734742188381},"volumeRatio":2.0584307403917297,"impliedVol":0.3431,"impliedVolPercentile":0.8571},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2492172953","title":"再生元制药公司跌2.09% 股价跌破700美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2492172953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492172953?lang=zh_cn&edition=full","pubTime":"2024-12-19 22:43","pubTimestamp":1734619391,"startTime":"0","endTime":"0","summary":"北京时间2024年12月19日22时43分，再生元制药公司股票出现波动，股价大幅下挫2.09%。截至发稿，该股报699.67美元/股，成交量6.0658万股，换手率0.06%，振幅1.67%。最近的财报数据显示，该股实现营业收入37.21亿美元，净利润13.41亿美元，每股收益12.40美元，毛利31.08亿美元，市盈率17.37倍。再生元制药公司股票所在的生物技术行业中，整体跌幅为2.75%。再生元制药公司公司简介：Regeneron Pharmaceuticals 发现、开发和商业化用于治疗眼部疾病、心血管疾病、癌症和炎症的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121922431195ea7afe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121922431195ea7afe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU2362541513.USD","LU0053666078.USD","LU0058720904.USD","LU0823416689.USD","LU1917777945.USD","LU2362540622.SGD","BK4139","BK4585","REGN","LU0114720955.EUR","LU2468319806.SGD","LU0882574055.USD","LU2106854487.HKD","LU1974910355.USD","LU0109394709.USD","LU2089984988.USD","LU2023250504.SGD","LU2362541273.HKD","LU0289739699.SGD","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2490551042","title":"BUZZ--美国股票走势-CoreCivic、Alphabet、韦尔度假村","url":"https://stock-news.laohu8.com/highlight/detail?id=2490551042","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490551042?lang=zh_cn&edition=full","pubTime":"2024-12-11 02:46","pubTimestamp":1733856413,"startTime":"0","endTime":"0","summary":".N美国东部时间13:30，道琼斯工业平均指数.DJI下跌0.01%，报44,398.56点。标普500指数.SPX下跌0.01%，报6,052.12点；纳斯达克综合指数.IXIC上涨0.14%，报19,764.94点。标准普尔 500 指数.PG.INX涨幅前三名是： ** 沃尔格林博姿联盟公司WBA.OQ，上涨 22.0. ** Alphabet Inc GOOG.OQ，上涨 5.0 标普500指数.PL.INX跌幅前三名： ** 甲骨文公司ORCL.N，下跌 7.7. ** 联合天然食品公司UNFI.N，上涨23.2%。** Cumberland Pharmaceuticals Inc CPIX.OQ，上涨 91.9 纳斯达克.PL.O百分比跌幅前三名： ** CervoMed Inc CRVO.OQ，下跌 76.9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nL4S3NB1I2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBAY","IE00BWXC8680.SGD","LU1935042991.SGD","REGN","IE0002270589.USD","SEI","SLB","LU1712237335.SGD","NEM","LU0640476718.USD","TARA","FERG","ORCL","MTN","TOL","PTVE","UPS","WBA","LU1721427968.SGD","VSCO","LU1571399168.USD","IAC","DBI","LU0345780281.USD","CRVO","PINS","KMI","NOV","MATW","OLLI","ASO","AJG","CXW","GIII","VNCE","CRDF","AMGN","CFG","LU0353189763.USD","JOUT","NCLH","LU2133065610.SGD","IE00B1XK9C88.USD","HAL","UNFI"],"gpt_icon":1},{"id":"2490010630","title":"BUZZ-美银美林恢复对安进、莫德纳、Regenron 的 \"跑输大盘 \"评级，股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2490010630","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490010630?lang=zh_cn&edition=full","pubTime":"2024-12-11 00:03","pubTimestamp":1733846585,"startTime":"0","endTime":"0","summary":"    12月10日 - ** 安进  、莫德纳  和Regeneron  股价下跌，此前博雅全球研究公司重新给予其 \"跑输大市 \"的评级。** BofA 将 AMGN 的目标价定为 256 美元；称肥胖症溢价将从股票中剥离，\"未来 10 年将有大量专利到期，这将对基本面造成压力\"。** BofA 将 MRNA 的目标价定为 41 美元；称现在是 \"疫苗公司的艰难时期\"。** BofA 将 REGN 的目标价定为 565 美元；称其主打药物 Eylea \"侵蚀速度/侵蚀程度高于共识\"。** 包括本交易日在内，AMGN 下跌 5.4%，MRNA 下跌 55.8%，REGN 下跌 12.4","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","MRNA","REGN"],"gpt_icon":1},{"id":"2490772677","title":"再生元制药公司涨2.83% 股价突破800美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2490772677","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490772677?lang=zh_cn&edition=full","pubTime":"2024-12-10 00:03","pubTimestamp":1733760234,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日00时03分，再生元制药公司股票出现波动，股价大幅上涨2.83%。截至发稿，该股报800.00美元/股，成交量26.8728万股，换手率0.24%，振幅3.46%。最近的财报数据显示，该股实现营业收入37.21亿美元，净利润13.41亿美元，每股收益12.40美元，毛利31.08亿美元，市盈率19.78倍。机构评级方面，在所有29家参与评级的机构中，66%的券商给予买入建议，31%的券商给予持有建议，3%的券商给予卖出建议。再生元制药公司股票所在的生物技术行业中，整体涨幅为1.00%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210000354ab6a39f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210000354ab6a39f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","BK4588","LU2468319806.SGD","LU2089984988.USD","LU0823416689.USD","LU1974910355.USD","LU0114720955.EUR","LU2106854487.HKD","REGN","LU0053666078.USD","LU2362541513.USD","BK4139","LU0889565916.HKD","LU2362540622.SGD","LU0058720904.USD","LU2362541273.HKD","LU0289739699.SGD","LU1917777945.USD","LU0882574055.USD","LU2023250504.SGD","LU0320765992.SGD","BK4585"],"gpt_icon":0},{"id":"2488965821","title":"2025年最具上涨空间的低价股","url":"https://stock-news.laohu8.com/highlight/detail?id=2488965821","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488965821?lang=zh_cn&edition=full","pubTime":"2024-12-03 14:13","pubTimestamp":1733206410,"startTime":"0","endTime":"0","summary":"摩根大通在11月25日的客户报告中表示：“展望2025年，生物科技的基本面预计将大体维持不变，随着企业在临床和监管上取得突破并在商业领域执行力强劲，这进一步凸显了创新的价值。”其中，AES的预期上涨空间最大（56%），动态市盈率最低，仅为6.6。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/03141345946693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0130518102.USD","SDS","SPXU","LU1720051017.SGD","UPRO","LU2468319806.SGD","DVN","LU1316542783.SGD","LU0648000940.SGD","BIIB","LU2357305700.SGD","CNC","IE00B19Z3B42.SGD",".SPX","BK4550","IE00B19Z9Z06.USD","LU0823434583.USD","LU0823434740.USD","LU2211814178.USD","IE0034235188.USD","SPY","AES","IVV","IE00B3CCJ633.GBP","BK4596","LU1201861249.SGD","LU0477156797.USD","LU0114720955.EUR","LU1366333091.USD","LU0320765992.SGD","LU0889565916.HKD","REGN","LU0061475181.USD","OEX","LU0823416689.USD","SSO","LU2272731782.SGD","OEF","FSLR","GB00BDT5M118.USD","SH","LU0056508442.USD","LU0157215616.USD","ESmain","MU","LU0792757196.USD","SLB","LU2357125470.USD","BK4554","LU2272731865.HKD"],"gpt_icon":1},{"id":"2486861822","title":"赛诺菲(SNY.US)/再生元(REGN.US)度普利尤单抗注射液在华再获批临床 治疗单纯性苔藓","url":"https://stock-news.laohu8.com/highlight/detail?id=2486861822","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486861822?lang=zh_cn&edition=full","pubTime":"2024-11-27 10:25","pubTimestamp":1732674301,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月26日，中国国家药监局药品审评中心网站最新公示，赛诺菲申报的度普利尤单抗注射液获批一项新的临床试验默示许可，拟开发用于治疗经外用药治疗控制不佳的中重度慢性单纯性苔藓成人患者。公开资料显示，在全球范围内，度普利尤单抗注射液正在针对单纯性苔藓适应症开展3期临床研究，本次是其针对该适应症首次在中国获批临床。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1216409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2362541273.HKD","SNY","LU0889565916.HKD","BK4139","BK4585","REGN","LU0320765992.SGD","LU1917777945.USD","LU2468319806.SGD","LU2362541513.USD","BK4588","IE00BFXG1179.USD","LU2023250504.SGD","LU0114720955.EUR","LU0109394709.USD","LU2089984988.USD","LU0823416689.USD","LU1974910355.USD","BK4007","LU0053666078.USD","LU0882574055.USD","LU0058720904.USD","LU0289739699.SGD","LU2362540622.SGD","LU2106854487.HKD"],"gpt_icon":0},{"id":"2484148792","title":"中国生物技术公司莱克纳与礼来合作开发保护肌肉的肥胖症药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2484148792","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484148792?lang=zh_cn&edition=full","pubTime":"2024-11-20 23:07","pubTimestamp":1732115272,"startTime":"0","endTime":"0","summary":"中国生物技术公司莱克纳与礼来合作开发保护肌肉的肥胖症药物路透11月20日 - 礼来LLY.N和香港上市公司Laekna2105.HK周三表示，将合作开发一种实验性肥胖症药物，旨在帮助患者减轻体重，同时保留肌肉。礼来公司将资助该药物的开发，并分享其资源和专业知识，但莱克纳公司将保留该药物的全球使用权，并计划在中国推进该药物的早期试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nL4T3MR17Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","LU1804176565.USD","SRRK","LU0079474960.USD","LU1868837300.USD","LU2237443895.HKD","LU2602419157.SGD","REGN","SG9999014898.SGD","SG9999018857.SGD","LU1974910355.USD","LU2362541513.USD","IE00BFTCPJ56.SGD","LU0354030438.USD","LU0385154629.USD","LU1035775433.USD","LU1551013342.USD","SG9999018865.SGD","LU2264538146.SGD","LU0096364046.USD","SG9999014906.USD","LU0122379950.USD","LU0320765992.SGD","LU1551013425.SGD","SG9999014914.USD","LLY","LU1868837136.USD","LU0823416689.USD","LU1064131342.USD","BK4588","02105","LU0058720904.USD","LU0820561909.HKD","GB00BDT5M118.USD","SG9999013999.USD","LU2063271972.USD","LU0471298777.SGD","LU1127390331.HKD","LU2361044949.HKD","LU0238689110.USD","LU0672654240.SGD","LU1069344957.HKD","LU0006306889.USD","LU0109391861.USD","LU1814569148.SGD","LU1917777945.USD","LU0256863811.USD","SG9999001176.USD","LU2237438978.USD","LU0198837287.USD"],"gpt_icon":1},{"id":"2483801494","title":"再生元制药公司跌0.55% 股价跌破800美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2483801494","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483801494?lang=zh_cn&edition=full","pubTime":"2024-11-14 22:30","pubTimestamp":1731594647,"startTime":"0","endTime":"0","summary":"北京时间2024年11月14日22时30分，再生元制药公司股票出现异动，股价大幅下挫0.55%。截至发稿，该股报799.90美元/股，成交量5341股，换手率0.00%，振幅0.00%。最近的财报数据显示，该股实现营业收入37.21亿美元，净利润13.41亿美元，每股收益12.40美元，毛利31.08亿美元，市盈率19.79倍。再生元制药公司股票所在的生物技术行业中，整体涨幅为0.00%。再生元制药公司公司简介：Regeneron Pharmaceuticals 发现、开发和商业化用于治疗眼部疾病、心血管疾病、癌症和炎症的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114223047971a68a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114223047971a68a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0289739699.SGD","LU0058720904.USD","LU0823416689.USD","LU2362540622.SGD","LU0109394709.USD","LU0320765992.SGD","LU2362541273.HKD","LU0053666078.USD","LU0889565916.HKD","LU1917777945.USD","LU2106854487.HKD","REGN","LU2362541513.USD","LU2089984988.USD","LU1974910355.USD","LU0882574055.USD","LU2468319806.SGD","BK4585","BK4139","BK4588","LU0114720955.EUR","LU2023250504.SGD"],"gpt_icon":0},{"id":"2482485937","title":"再生元制药公司2024财年第三财季实现净利润13.41亿美元，同比增加33.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482485937","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482485937?lang=zh_cn&edition=full","pubTime":"2024-11-09 00:00","pubTimestamp":1731081626,"startTime":"0","endTime":"0","summary":"11月9日，再生元制药公司公布财报，公告显示公司2024财年第三财季净利润为13.41亿美元，同比增加33.04%；其中营业收入为37.21亿美元，同比增加10.65%，每股基本收益为12.40美元。从资产负债表来看，再生元制药公司总负债81.16亿美元，其中短期债务0.00美元，资产负债比为4.62，流动比率为5.29。机构评级：截至2024年11月9日，当前有22家机构对再生元制药公司目标价做出预测，其中目标均价为1096.68美元，其中最低目标价为800.00美元，最高目标价为1230.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109000120a224f5d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109000120a224f5d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REGN"],"gpt_icon":0},{"id":"2481774918","title":"11月投资预警：超买、超卖股票名单曝光，回调与反弹机会一览","url":"https://stock-news.laohu8.com/highlight/detail?id=2481774918","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481774918?lang=zh_cn&edition=full","pubTime":"2024-11-07 08:11","pubTimestamp":1730938264,"startTime":"0","endTime":"0","summary":"在最近的市场回调中，投资者开始增持多家知名公司的股票，如GE Vernova和联合航空等。然而，根据一种流行的技术指标，这些超买的股票可能会面临回调。14天RSI超过70的公司通常被视为超买，可能预示着回调，而RSI低于30的股票通常被视为超卖，未来有上涨的可能。GE Vernova在过去一个月上涨了19%，目前14天RSI为76.9。周五股价一度上涨3.3%，创下历史新高。联合航空是另一只超买的股票，其14天RSI为78.7。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/11/07081145019017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4008","LU2552382215.SGD","EBAY","RSI","BK4150","LU0114720955.EUR","LU2404859741.USD","LU2404859667.USD","GEV","BK4566","EL","LU0289739699.SGD","LU0724618433.USD","LU1815336760.USD","LU2089984988.USD","LU1917777945.USD","LU1974910355.USD","LU2023250504.SGD","REGN","BK4177","LU0889565916.HKD","LU0058720904.USD","BK4535","BK4500","BK4183","BK4139","BK4524","LU2264538146.SGD","LU2298322129.HKD","UAL","LU1093756168.USD","LU1093756325.SGD","LU1642822529.SGD","KDP","BK4533","LU2362540622.SGD","LU0320765992.SGD","LU1978683503.SGD","LU1303367103.USD","LU0690374961.EUR","LU2098885051.SGD","LU2362541273.HKD","LU0444973449.USD","LU1059921491.USD","IE00BJTD4N35.SGD","LU1064131342.USD","LU1988902786.USD","LU0690374615.EUR","BK4182","BK4504"],"gpt_icon":1},{"id":"2480026060","title":"美国研究综述-亚马逊、IQVIA 控股、优步","url":"https://stock-news.laohu8.com/highlight/detail?id=2480026060","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480026060?lang=zh_cn&edition=full","pubTime":"2024-11-01 14:25","pubTimestamp":1730442324,"startTime":"0","endTime":"0","summary":"    路透11月1日 - 华尔街证券分析师周五调整了对亚马逊、IQVIA Holdings 和 Uber 等多家美国上市公司的评级和目标价。要闻             * 亚马逊  ：摩根大通将目标价从230美元上调至250美元             * 切尼尔能源公司  ：雷蒙德-詹姆斯将目标价从210美元上调至225美元             * IQVIA Holdings Inc   ：TD Cowen将目标价从270美元下调至255美元             * Regeneron Pharmaceuticals Inc   ：Truist Securities将目标价从1,137美元下调至1,126美元             * Uber   ：Piper Sandler将目标价从88美元上调至98美元 以下是路透周五报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"bc4ea46c42970863736c661918072cd0","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFSS7M15.SGD","LU1791710400.SGD","IE00BJT1NW94.SGD","LU0528227936.USD","CI","X","AX","CCK","NSP","LU0306807586.USD","SUM","LU0094547139.USD","IE00BJJMRX11.SGD","STEL","KTB","IE00B19Z9P08.USD","LAZ","ALGT","ALNY","AVNT","LU1670711123.USD","BK4500","UBER","TREE","EBAY","COHU","H","IQV","LU1894683264.USD","MGY","NAVI","COP","CMCSA","BK4550","IE00B7SZLL34.SGD","MCW","REGN","INSM","LU0077335932.USD","UTZ","AMZN","BMY","DASH","MA","LNG","SN"],"gpt_icon":1},{"id":"1156333101","title":"异动解读 | 旗舰新药销售未达预期,再生元制药股价重挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1156333101","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156333101?lang=zh_cn&edition=full","pubTime":"2024-11-01 11:47","pubTimestamp":1730432839,"startTime":"0","endTime":"0","summary":"再生元制药公司今日股价盘中一度大跌11.55%,引发了市场的广泛关注和担忧。此次大跌的主要原因是公司旗舰眼科药物Eylea的高剂量新版本在第三季度的销售数据低于市场预期。Eylea一直是再生元制药最重要的收入来源,被视为其摇钱树产品。在竞争日趋白热化的情况下,再加上旗舰新药销售未达预期,投资者对再生元制药公司的信心受到打击,导致股价在盘中出现重挫。公司当前面临的主要挑战是如何提升Eylea高剂量版本的销售增长,重塑市场信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["REGN"],"gpt_icon":0},{"id":"1197684840","title":"异动解读 | 再生元制药新药销售未达预期 引发市场对长期增长前景担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1197684840","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197684840?lang=zh_cn&edition=full","pubTime":"2024-11-01 04:53","pubTimestamp":1730407988,"startTime":"0","endTime":"0","summary":"再生元制药公司今日股价大跌11.55%,引发市场广泛关注。公司盘前股价下跌5.18%,随后跌幅进一步扩大,一度重挫近10%,截至收盘仍大跌6.78%。导致此次重挫的主要原因是公司在第三季度财报中公布的旗舰产品Eylea高剂量新版本的销售数据低于市场预期。Eylea是再生元制药公司最重要的收入来源,被视为其摇钱树产品。但销售未达预期引发市场对该公司转型战略和长期增长前景的担忧。虽然总体Eylea销售额达到15.4亿美元,同比增长3%,但新药销售放缓令投资者失望。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["REGN"],"gpt_icon":0},{"id":"2480205153","title":"BUZZ--美国股票走势-雅诗兰黛、DoorDash、Peloton Interactive","url":"https://stock-news.laohu8.com/highlight/detail?id=2480205153","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480205153?lang=zh_cn&edition=full","pubTime":"2024-11-01 01:26","pubTimestamp":1730395596,"startTime":"0","endTime":"0","summary":"        *      Eikon 个股走势搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      10月31日 - 华尔街周四下跌，原因是微软和 Meta Platforms 就人工智能成本飙升发出的警告打击了市场对大型股的热情，而这些大型股今年以来一直领涨市场。美东时间13:03，道琼斯工业平均指数  报41950.41点，下跌0.4%。标普500指数  下跌1.34%，报5735.53点；纳斯达克综合指数  下跌2.31%，报18177.527点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TQQQ","WEN","IP","ETSY","CWH","DASH","AVGO","SDOW","COP","DOG","XEL","EL","PTON","TFX","LNG","IDXX","SQQQ",".DJI","HRMY","QLD","MNQmain","MSFT","CVX","META","IQV","ENVX","DXD","QID","DJX","MO","RELY","BMY","CMCSA","EBAY","NXT","MRK","REGN","NCLH","KIM","PBF","SO",".IXIC",".SPX","APLD","CI","DDM","BALL"],"gpt_icon":1},{"id":"2479032990","title":"更新版 1-Regeneron股价下跌，原因是高剂量Eylea药物的销售额低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2479032990","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479032990?lang=zh_cn&edition=full","pubTime":"2024-10-31 23:23","pubTimestamp":1730388225,"startTime":"0","endTime":"0","summary":"  Christy Santhosh    路透10月31日 - 美国制药商Regeneron Pharmaceuticals   周四公布的财报显示，其高剂量版眼病治疗药物Eylea的季度销售额低于预期，导致其股价下跌9%。高剂量 版Eylea HD的季度销售额 为 3.92 亿美元，连续第二个季度低于预期 。Regeneron表示，Eylea的净销售额因 第三季度末高剂量版本的 批发商库存水平上升而增加 了约 4000万美元。Regeneron 的总收入为 37.2 亿美元，超过了预期的 36.7 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0058720904.USD","BK4585","LU0823416689.USD","LU0889565916.HKD","LU1917777945.USD","LU2362540622.SGD","LU0320765992.SGD","LU2023250504.SGD","LU0109394709.USD","LU2106854487.HKD","LU2089984988.USD","REGN","LU1974910355.USD","LU0882574055.USD","LU2362541273.HKD","LU0114720955.EUR","LU0053666078.USD","LU0289739699.SGD","LU2468319806.SGD","LU2362541513.USD","BK4588"],"gpt_icon":0},{"id":"1165527825","title":"异动解读 | 再生元制药公司盘中重挫逾6% 旗舰产品Eylea新药销售未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1165527825","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165527825?lang=zh_cn&edition=full","pubTime":"2024-10-31 21:50","pubTimestamp":1730382610,"startTime":"0","endTime":"0","summary":"再生元制药公司  今日盘中重挫6.78%,引发市场广泛关注。公司盘前股价下跌5.18%,随后跌幅进一步扩大。根据公司公布的第三季度财报,旗舰眼科药物Eylea新推出的高剂量版本销售额为3.92亿美元,低于分析师预期的4.17亿美元。Eylea是再生元制药公司最重要的收入来源,一直被视为其摇钱树产品。再生元制药公司一直在努力将使用传统Eylea的患者升级至新的高剂量版本,但效果不佳。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["REGN"],"gpt_icon":0},{"id":"2479331420","title":"再生元制药公司盘中异动 股价大跌6.01%报867.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479331420","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479331420?lang=zh_cn&edition=full","pubTime":"2024-10-31 21:31","pubTimestamp":1730381509,"startTime":"0","endTime":"0","summary":"北京时间2024年10月31日21时31分，再生元制药公司股票出现异动，股价急速跳水6.01%。截至发稿，该股报867.32美元/股，成交量4.3549万股，换手率0.04%，振幅2.80%。再生元制药公司股票所在的生物技术行业中，整体跌幅为1.28%。其相关个股中，Aerovate Therapeutics, Inc.、180 Life Sciences Corp C/Wts 07/11/2025、Mimedx Group, Inc涨幅较大，Evogene Ltd.、Aditxt, Inc.、Palisade Bio, Inc.较为活跃，换手率分别为190.75%、186.08%、144.98%，振幅较大的相关个股有180 Life Sciences Corp C/Wts 07/11/2025、Equillium, Inc.、Aerovate Therapeutics, Inc.，振幅分别为21.98%、14.49%、9.59%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103121314995bd9be4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103121314995bd9be4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0114720955.EUR","LU2106854487.HKD","LU0053666078.USD","LU2362541513.USD","LU0289739699.SGD","BK4585","BK4139","LU0109394709.USD","LU0320765992.SGD","LU1974910355.USD","LU2362541273.HKD","REGN","LU2362540622.SGD","LU2089984988.USD","LU0058720904.USD","LU0823416689.USD","LU2023250504.SGD","LU0882574055.USD","LU2468319806.SGD","LU0889565916.HKD","LU1917777945.USD","BK4588"],"gpt_icon":0},{"id":"1194151052","title":"异动解读 | 再生元制药盘前大跌5% 新药Eylea销售未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1194151052","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194151052?lang=zh_cn&edition=full","pubTime":"2024-10-31 21:26","pubTimestamp":1730381192,"startTime":"0","endTime":"0","summary":"再生元制药公司(Regeneron)今日盘前股价大跌5.18%,引发市场关注。主要原因似乎是该公司旗舰眼科药物Eylea新推出的高剂量版本销售未达预期所致。\n\n数据显示,再生元制药第三季度公布Eylea高剂量版本销售额为3.92亿美元,低于分析师预期的4.17亿美元。该公司一直在努力将使用传统Eylea的患者升级至新的高剂量版本,但效果不佳。\n\n这种销售增长放缓令投资者失望,因为Eylea是再生元的摇钱树产品,而此次新药销售未达预期。此外,由于Eylea还面临着包括罗氏的Vabysmo在内的竞争对手的激烈竞争,再加上未来可能出现生物仿制药的威胁,导致市场对公司长期增长前景失去信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 再生元制药盘前大跌5% 新药Eylea销售未达预期","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["REGN"],"gpt_icon":0},{"id":"2479091089","title":"BUZZ-Regeneron因高剂量版眼药销售未达预期而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2479091089","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479091089?lang=zh_cn&edition=full","pubTime":"2024-10-31 20:41","pubTimestamp":1730378460,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    10月31日 - ** 制药公司再生元制药  股价盘前下跌1.9%至904.99美元** Regeneron 公布其眼科药物 Eylea 的高剂量版第三季度销售额为 3.92 亿美元，低于分析师预期的 4.17 亿美元 - LSEG 数据** 该公司正试图将使用 Eylea 的患者升级到高剂量版本** (link) 报告显示，该公司 第三季度 每股收益为 12.46 美元，分析师预计为 11.69 美元。** 今年以来股价上涨 5.1%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","BK4585","LU2106854487.HKD","LU0889565916.HKD","LU0114720955.EUR","LU2468319806.SGD","REGN","LU2089984988.USD","LU0289739699.SGD","LU2362541513.USD","LU1974910355.USD","LU1917777945.USD","LU0058720904.USD","LU0109394709.USD","LU0053666078.USD","LU0823416689.USD","LU0320765992.SGD","BK4588","LU2362540622.SGD","BK4139","LU2023250504.SGD","LU0882574055.USD"],"gpt_icon":0},{"id":"2479702987","title":"由于湿疹治疗和眼科药物的需求，Regeneron 业绩超出预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2479702987","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479702987?lang=zh_cn&edition=full","pubTime":"2024-10-31 19:21","pubTimestamp":1730373701,"startTime":"0","endTime":"0","summary":"    路透10月31日 - 美国制药商Regeneron Pharmaceuticals  周四公布的第三季度利润和营收超出华尔街预期，主要受湿疹治疗药物Dupixent和眼疾治疗药物Eylea需求强劲的推动。根据 LSEG 编制的数据，Regeneron 的总收入为 37.2 亿美元 ，超过了预期的 36.7 亿美元 。该制药公司的抗炎药物 Dupixent 的销售额为 38.2 亿美元，高于预期的   37.8 亿美元。Dupixent目前被批准用于治疗六种疾病，包括哮喘、一种名为特应性皮炎的皮肤病，最近 ，作为慢性阻塞性肺病的附加治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0058720904.USD","BK4585","LU0823416689.USD","LU0889565916.HKD","LU1917777945.USD","LU2362540622.SGD","LU0320765992.SGD","LU2023250504.SGD","LU0109394709.USD","LU2106854487.HKD","LU2089984988.USD","REGN","LU1974910355.USD","LU0882574055.USD","LU2362541273.HKD","LU0114720955.EUR","LU0053666078.USD","LU0289739699.SGD","LU2468319806.SGD","LU2362541513.USD","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0403},{"period":"1month","weight":-0.0558},{"period":"3month","weight":-0.387},{"period":"6month","weight":-0.3336},{"period":"1year","weight":-0.1663},{"period":"ytd","weight":-0.2009}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州成立。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。其正在开发的商业化药物和候选产品旨在帮助患有眼疾、过敏性和炎症性疾病、癌症、心血管和代谢性疾病、疼痛、传染病和罕见疾病的患者。它的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.041845},{"month":2,"riseRate":0.393939,"avgChangeRate":0.089316},{"month":3,"riseRate":0.484848,"avgChangeRate":-0.042863},{"month":4,"riseRate":0.484848,"avgChangeRate":0.019407},{"month":5,"riseRate":0.647059,"avgChangeRate":0.064499},{"month":6,"riseRate":0.411765,"avgChangeRate":0.00486},{"month":7,"riseRate":0.647059,"avgChangeRate":0.053048},{"month":8,"riseRate":0.529412,"avgChangeRate":0.02165},{"month":9,"riseRate":0.470588,"avgChangeRate":0.0249},{"month":10,"riseRate":0.382353,"avgChangeRate":-0.006135},{"month":11,"riseRate":0.529412,"avgChangeRate":0.041578},{"month":12,"riseRate":0.5,"avgChangeRate":0.044994}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}